Navigation Links
Aerovance Secures $20 Million in Debt Financing
Date:3/28/2008

BERKELEY, Calif., March 28 /PRNewswire/ -- Aerovance Inc. today announced it has secured $20 million in venture debt financing. Oxford Finance Corporation led the syndicate, which includes Silicon Valley Bank and Comerica Bank. Aerovance drew down $10 million from the financing line at closing. The remaining $10 million is available upon the achievement of corporate milestones.

"This financing reflects continued interest and enthusiasm in Aerovance and our clinical programs," said Mark Perry, Aerovance's president and chief executive officer. "With this additional capital, we will continue to pursue our strategic goals, including a global partnership for our lead program, Aerovant(TM), and to build value in the company through development of our respiratory and inflammatory disease candidates."

Aerovant(TM) is a recombinant human IL-4 variant that is a potent inhibitor of both the IL-4 and IL-13 receptors. Aerovance acquired the worldwide rights to the drug candidate when the company was formed as a spin-out of Bayer Pharmaceuticals Corporation in 2004.

Aerovance Inc. is a Berkeley, Calif.-based biopharmaceutical company focused on the development and commercialization of breakthrough therapies for the treatment of respiratory and inflammatory diseases. For more information, visit http://www.aerovance.com.


'/>"/>
SOURCE Aerovance Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amarin Secures Global Intellectual Property Rights for Lipid Programs
2. Ranier Technology Secures GBP8m Funding for its Cadisc Replacement Spinal Discs
3. Halogen Announces Record Year - Company Solidifies Leadership Position, Secures Strategic Wins Over Competition
4. Taligen Therapeutics Secures Series B Financing
5. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
6. Dendreon Secures $130 Million Committed Equity Financing Facility
7. Apollo Endosurgery, Inc. Secures $11.5 Million in Series A Financing.
8. Altheus Therapeutics Secures $3.6 Million in Venture Capital
9. Weil Gotshal Wins Major Victory for Applera; Secures Summary Judgment Invalidating Three Patents
10. Hyperion Therapeutics Secures $40 Million In Series B Round
11. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 01, 2016 , ... ACEA Biosciences, Inc. announced ... I/II clinical trials for AC0010 at the World Conference on Lung Cancer 2016, taking ... update on the phase I/II clinical trials for AC0010 in patients with advanced non-small ...
(Date:12/2/2016)... ... December 01, 2016 , ... The Conference Forum has announced ... days and will take place on February 1-3, 2017 at the Roosevelt Hotel in ... (NCI), the program provides a unique 360-degree approach, which addresses the most up-to-date information ...
(Date:12/2/2016)... ... 2016 , ... Robots will storm the Prudential Center in Boston, MA during ... which is held on the United Nations International Day of Persons with Disabilities, will ... workplace. Suitable Technologies is partnering with NTI to showcase how technology can help individuals ...
(Date:11/30/2016)... ... November 30, 2016 , ... BEI Kimco, a brand of ... flexure design that ensures high alignment accuracy by preventing unwanted shaft rotation. The ... where extreme precision is required, such as in medical equipment, laboratory instrumentation, clean ...
Breaking Biology Technology:
(Date:11/29/2016)... CANNES, France , November 29, 2016 Nearly ... Continue Reading ... ... System is part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric ...
(Date:11/21/2016)...   Neurotechnology , a provider of high-precision ... that the MegaMatcher On Card fingerprint matching algorithm ... NIST Minutiae Interoperability Exchange (MINEX) III ... of the evaluation protocol. The ... fingerprint templates used to establish compliance of template ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, ... developing therapeutics focused on the gut microbiome, today ... of 25,000,000 shares of its common stock and ... stock at a price to the public of ... to Synthetic Biologics from the offering, excluding the ...
Breaking Biology News(10 mins):